应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
VRNA 维罗纳制药
未开盘 11-18 16:00:00 EST
34.94
-0.72
-2.02%
盘后
34.94
+0.00
0.00%
18:34 EST
最高
36.10
最低
34.51
成交量
111.86万
今开
35.52
昨收
35.66
日振幅
4.46%
总市值
28.59亿
流通市值
2.21亿
总股本
8,183万
成交额
3,946万
换手率
17.70%
流通股本
631.89万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
维罗纳制药盘中异动 临近收盘急速下跌5.09%
市场透视 · 11-15
维罗纳制药盘中异动 临近收盘急速下跌5.09%
维罗纳制药盘中异动 急速下挫5.03%报37.04美元
市场透视 · 11-14
维罗纳制药盘中异动 急速下挫5.03%报37.04美元
维罗纳制药2024财年第三财季实现净利润-43.40百万美元,同比减少197.26%
市场透视 · 11-10
维罗纳制药2024财年第三财季实现净利润-43.40百万美元,同比减少197.26%
异动解读 | 维罗纳制药股价盘中重挫 公司财报数据或成主因
异动解读 · 11-04
异动解读 | 维罗纳制药股价盘中重挫 公司财报数据或成主因
维罗纳制药盘中异动 早盘股价大跌6.92%
市场透视 · 11-04
维罗纳制药盘中异动 早盘股价大跌6.92%
美股异动 | 维罗纳制药盘前续涨3.6% 开盘有望再刷新高
港股那点事 · 10-15
美股异动 | 维罗纳制药盘前续涨3.6% 开盘有望再刷新高
维罗纳制药盘中异动 股价大涨5.00%
市场透视 · 10-15
维罗纳制药盘中异动 股价大涨5.00%
维罗纳制药盘中异动 下午盘快速上涨5.04%报32.95美元
市场透视 · 10-12
维罗纳制药盘中异动 下午盘快速上涨5.04%报32.95美元
维罗纳制药盘中异动 早盘大幅拉升5.68%报32.56美元
市场透视 · 10-04
维罗纳制药盘中异动 早盘大幅拉升5.68%报32.56美元
维罗纳制药盘中异动 早盘快速上涨5.19%报30.20美元
市场透视 · 10-03
维罗纳制药盘中异动 早盘快速上涨5.19%报30.20美元
维罗纳制药盘中异动 大幅拉升5.07%
市场透视 · 09-27
维罗纳制药盘中异动 大幅拉升5.07%
维罗纳制药2024财年第二财季实现净利润-70.91百万美元,同比减少702.15%
自选股智能写手 · 08-18
维罗纳制药2024财年第二财季实现净利润-70.91百万美元,同比减少702.15%
异动解读 | 维罗纳制药股价大涨5.2% 市场关注其呼吸系统疾病药物研发进展
异动解读 · 08-15
异动解读 | 维罗纳制药股价大涨5.2% 市场关注其呼吸系统疾病药物研发进展
维罗纳制药盘中异动 股价大涨5.16%
自选股智能写手 · 08-15
维罗纳制药盘中异动 股价大涨5.16%
维罗纳制药盘中异动 快速上涨5.31%
自选股智能写手 · 08-13
维罗纳制药盘中异动 快速上涨5.31%
异动解读 | 维罗纳制药股价大涨5.53% 机构看好公司前景
异动解读 · 08-13
异动解读 | 维罗纳制药股价大涨5.53% 机构看好公司前景
维罗纳制药盘中异动 急速拉升5.35%
自选股智能写手 · 08-12
维罗纳制药盘中异动 急速拉升5.35%
异动解读 | 维罗纳制药股价大涨5.65% 机构看好公司前景
异动解读 · 08-09
异动解读 | 维罗纳制药股价大涨5.65% 机构看好公司前景
维罗纳制药盘中异动 早盘急速拉升5.42%报22.77美元
自选股智能写手 · 08-09
维罗纳制药盘中异动 早盘急速拉升5.42%报22.77美元
异动解读 | 维罗纳制药股价大涨5%,机构看好公司前景
异动解读 · 08-09
异动解读 | 维罗纳制药股价大涨5%,机构看好公司前景
加载更多
公司概况
公司名称:
维罗纳制药
所属市场:
NASDAQ
上市日期:
--
主营业务:
维罗纳制药公司根据英格兰及威尔士的法律以Isis Resources plc为名于2005年2月24日注册成立。2006年9月,该公司收购了在加拿大注册成立的私人公司Rhinopharma Limited,并更名为维罗纳制药公司。该公司是一家临床阶段的生物制药公司,专注于开发和商业化创新治疗方法,用于治疗具有显著未满足的医疗需求的呼吸系统疾病。
发行价格:
--
{"stockData":{"symbol":"VRNA","market":"US","secType":"STK","nameCN":"维罗纳制药","latestPrice":34.94,"timestamp":1731963600000,"preClose":35.66,"halted":0,"volume":1118643,"hourTrading":{"tag":"盘后","latestPrice":34.94,"preClose":34.94,"latestTime":"18:34 EST","volume":231045,"amount":8073090.6805,"timestamp":1731972858344},"delay":0,"floatShares":6318900,"shares":81831169,"eps":-1.934086,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.72,"latestTime":"11-18 16:00:00 EST","open":35.52,"high":36.1,"low":34.51,"amount":39461281.79000399,"amplitude":0.044588,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.934086,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732006800000},"adr":1,"listingDate":1493265600000,"adjPreClose":35.66,"adrRate":8,"preHourTrading":{"tag":"盘前","latestPrice":36,"preClose":35.66,"latestTime":"09:17 EST","volume":475,"amount":17092.070825000003,"timestamp":1731939475452},"postHourTrading":{"tag":"盘后","latestPrice":34.94,"preClose":34.94,"latestTime":"18:34 EST","volume":231045,"amount":8073090.6805,"timestamp":1731972858344},"volumeRatio":0.94223,"impliedVol":0.3742,"impliedVolPercentile":0.012},"requestUrl":"/m/hq/s/VRNA","defaultTab":"news","newsList":[{"id":"2483334424","title":"维罗纳制药盘中异动 临近收盘急速下跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483334424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483334424?lang=zh_cn&edition=full","pubTime":"2024-11-15 04:48","pubTimestamp":1731617290,"startTime":"0","endTime":"0","summary":"北京时间2024年11月15日04时48分,维罗纳制药股票出现波动,股价大幅下挫5.09%。截至发稿,该股报35.05美元/股,成交量72.3206万股,换手率0.88%,振幅5.36%。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为2.05%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115044810a2388d57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115044810a2388d57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2483437857","title":"维罗纳制药盘中异动 急速下挫5.03%报37.04美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483437857","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483437857?lang=zh_cn&edition=full","pubTime":"2024-11-14 04:49","pubTimestamp":1731530954,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日04时49分,维罗纳制药股票出现异动,股价大幅下跌5.03%。截至发稿,该股报37.04美元/股,成交量65.8269万股,换手率0.80%,振幅6.28%。最近的财报数据显示,该股实现营业收入5.68百万美元,净利润-43.40百万美元,每股收益-0.57美元,毛利4.86百万美元,市盈率-18.57倍。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为0.54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111404491598e42751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111404491598e42751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2482422272","title":"维罗纳制药2024财年第三财季实现净利润-43.40百万美元,同比减少197.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482422272","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482422272?lang=zh_cn&edition=full","pubTime":"2024-11-10 00:02","pubTimestamp":1731168134,"startTime":"0","endTime":"0","summary":"11月10日,维罗纳制药公布财报,公告显示公司2024财年第三财季净利润为-43.40百万美元,同比减少197.26%;其中营业收入为5.68百万美元,每股基本收益为-0.57美元。从资产负债表来看,维罗纳制药总负债2.51亿美元,其中短期债务952000.00美元,资产负债比为1.53,流动比率为0.14。机构评级:截至2024年11月10日,当前有8家机构对维罗纳制药目标价做出预测,其中目标均价为45.81美元,其中最低目标价为36.00美元,最高目标价为64.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000240abb100b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000240abb100b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA"],"gpt_icon":0},{"id":"1186579180","title":"异动解读 | 维罗纳制药股价盘中重挫 公司财报数据或成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1186579180","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186579180?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:50","pubTimestamp":1730731826,"startTime":"0","endTime":"0","summary":"2024年11月4日,生物制药公司维罗纳制药股价在早盘出现震荡下跌,跌幅一度达到6.92%,引发市场关注。分析人士指出,可能与公司最新财报数据不佳有关。根据报道,维罗纳制药最新公布的财报数据显示,公司目前营业收入为0美元,净亏损高达7091万美元,每股亏损0.88美元。公司业务主要集中在呼吸系统疾病相关药品的研发,目前重点产品为针对慢性阻塞性肺疾病等疾病的\"Ensifentrine\"候选药物。值得注意的是,公司财务状况和业绩增长前景备受市场质疑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VRNA"],"gpt_icon":0},{"id":"2480581410","title":"维罗纳制药盘中异动 早盘股价大跌6.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480581410","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480581410?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:32","pubTimestamp":1730730739,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时32分,维罗纳制药股票出现波动,股价急速下跌6.92%。截至发稿,该股报32.56美元/股,成交量11.2643万股,换手率0.14%,振幅4.46%。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为0.23%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422321995bdc9e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422321995bdc9e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2475528765","title":"美股异动 | 维罗纳制药盘前续涨3.6% 开盘有望再刷新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2475528765","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475528765?lang=zh_cn&edition=full","pubTime":"2024-10-15 16:54","pubTimestamp":1728982440,"startTime":"0","endTime":"0","summary":"维罗纳制药(VRNA.US)盘前续涨3.61%,开盘有望再刷历史新高。近日公司获诸多大行唱好:储亿银行分析师Joon Lee维持维罗纳制药“买入”评级,目标价38美元;Truist证券将其目标价从38美元上调至44美元;派杰投资维持公司“买入”评级,维持目标价36美元。(格隆汇)\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-10-15/doc-incsrqpw7593030.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-10-15/doc-incsrqpw7593030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2475182303","title":"维罗纳制药盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475182303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475182303?lang=zh_cn&edition=full","pubTime":"2024-10-15 01:00","pubTimestamp":1728925240,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日01时00分,维罗纳制药股票出现异动,股价急速上涨5.00%。截至发稿,该股报34.31美元/股,成交量58.1356万股,换手率0.72%,振幅5.51%。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为0.71%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101501004098e3c51d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101501004098e3c51d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2474041514","title":"维罗纳制药盘中异动 下午盘快速上涨5.04%报32.95美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474041514","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474041514?lang=zh_cn&edition=full","pubTime":"2024-10-12 03:29","pubTimestamp":1728674953,"startTime":"0","endTime":"0","summary":"北京时间2024年10月12日03时29分,维罗纳制药股票出现波动,股价快速上涨5.04%。截至发稿,该股报32.95美元/股,成交量71.9567万股,换手率0.89%,振幅5.77%。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为1.20%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241012032913a1e00b08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241012032913a1e00b08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2472950068","title":"维罗纳制药盘中异动 早盘大幅拉升5.68%报32.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472950068","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472950068?lang=zh_cn&edition=full","pubTime":"2024-10-04 22:14","pubTimestamp":1728051249,"startTime":"0","endTime":"0","summary":"北京时间2024年10月04日22时14分,维罗纳制药股票出现波动,股价急速上涨5.68%。截至发稿,该股报32.56美元/股,成交量24.1766万股,换手率0.30%,振幅5.15%。最近的财报数据显示,该股实现营业收入0.00美元,净利润-70.91百万美元,每股收益-0.88美元,毛利-270302.68美元,市盈率-20.19倍。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为0.26%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100422140998e3a9c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100422140998e3a9c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2472616430","title":"维罗纳制药盘中异动 早盘快速上涨5.19%报30.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472616430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472616430?lang=zh_cn&edition=full","pubTime":"2024-10-03 21:33","pubTimestamp":1727962387,"startTime":"0","endTime":"0","summary":"北京时间2024年10月03日21时33分,维罗纳制药股票出现异动,股价快速拉升5.19%。截至发稿,该股报30.20美元/股,成交量8.404万股,换手率0.10%,振幅2.40%。最近的财报数据显示,该股实现营业收入0.00美元,净利润-70.91百万美元,每股收益-0.88美元,毛利-270302.68美元,市盈率-18.68倍。机构评级方面,在所有8家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为0.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003213307ab679855&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003213307ab679855&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2470352630","title":"维罗纳制药盘中异动 大幅拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470352630","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470352630?lang=zh_cn&edition=full","pubTime":"2024-09-27 23:59","pubTimestamp":1727452788,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日23时59分,维罗纳制药股票出现异动,股价大幅拉升5.07%。截至发稿,该股报29.04美元/股,成交量22.795万股,换手率0.28%,振幅5.28%。机构评级方面,在所有7家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为0.42%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092723594898e3971e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092723594898e3971e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"2460673692","title":"维罗纳制药2024财年第二财季实现净利润-70.91百万美元,同比减少702.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460673692","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460673692?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:03","pubTimestamp":1723910592,"startTime":"0","endTime":"0","summary":"8月18日,维罗纳制药公布财报,公告显示公司2024财年第二财季净利润为-70.91百万美元,同比减少702.15%;其中营业收入为0.00美元,每股基本收益为-0.88美元。从资产负债表来看,维罗纳制药总负债2.66亿美元,其中短期债务1.03百万美元,资产负债比为1.64,流动比率为0.09。机构评级:截至2024年8月18日,当前有7家机构对维罗纳制药目标价做出预测,其中目标均价为35.79美元,其中最低目标价为31.50美元,最高目标价为38.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800045795a1662a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800045795a1662a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA"],"gpt_icon":0},{"id":"1199236678","title":"异动解读 | 维罗纳制药股价大涨5.2% 市场关注其呼吸系统疾病药物研发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1199236678","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199236678?lang=zh_cn&edition=full","pubTime":"2024-08-15 23:04","pubTimestamp":1723734291,"startTime":"0","endTime":"0","summary":"北京时间2024年8月15日,生物制药公司维罗纳制药(VRNA.US)股价出现大涨,盘中一度上涨5.2%,报28.72美元/股,成交量和换手率均有所上升。\n\n维罗纳制药是一家专注于开发治疗呼吸系统疾病新药的临床阶段生物制药公司。该公司目前正在研发一种名为Ensifentrine的候选药物,用于治疗慢性阻塞性肺疾病、囊性纤维化等呼吸系统疾病。\n\n虽然公司近期没有发布重大利好消息,但分析人士认为,投资者对该公司在呼吸系统疾病药物研发领域的前景抱有较高期望,这可能是推动股价上涨的主要原因。此外,生物技术行业整体表现向好,也为维罗纳制药股价带来一定提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2459795404","title":"维罗纳制药盘中异动 股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459795404","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459795404?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:46","pubTimestamp":1723733205,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日22时46分,维罗纳制药股票出现波动,股价快速上涨5.16%。截至发稿,该股报28.72美元/股,成交量52.1512万股,换手率0.64%,振幅6.04%。机构评级方面,在所有7家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为0.93%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815224645a1d47435&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815224645a1d47435&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VRNA","BK4007"],"gpt_icon":0},{"id":"2459188298","title":"维罗纳制药盘中异动 快速上涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459188298","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459188298?lang=zh_cn&edition=full","pubTime":"2024-08-13 22:59","pubTimestamp":1723561188,"startTime":"0","endTime":"0","summary":"北京时间2024年08月13日22时59分,维罗纳制药股票出现异动,股价急速上涨5.31%。截至发稿,该股报25.99美元/股,成交量78.2032万股,换手率0.96%,振幅8.55%。机构评级方面,在所有7家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为1.79%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813225949aefea078&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240813225949aefea078&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"1177799807","title":"异动解读 | 维罗纳制药股价大涨5.53% 机构看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1177799807","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177799807?lang=zh_cn&edition=full","pubTime":"2024-08-13 00:02","pubTimestamp":1723478547,"startTime":"0","endTime":"0","summary":"北京时间2024年8月12日,生物制药公司维罗纳制药(VRNA.US)股价出现大涨,盘中一度上涨5.53%,报23.83美元/股,成交量和换手率均显著增加。\n\n维罗纳制药是一家专注于开发治疗呼吸系统疾病新药的临床阶段生物制药公司。公司目前正在开发Ensifentrine候选产品,用于治疗慢性阻塞性肺疾病、囊性纤维化等疾病。\n\n分析人士认为,维罗纳制药股价大涨或与机构投资者对公司前景的看好有关。最新数据显示,7家参与评级的机构中,100%给予该股买入评级。此外,公司最新财报显示营收和净利润虽然为负值,但市盈率处于合理水平,未来仍有较大增长空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2459493827","title":"维罗纳制药盘中异动 急速拉升5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459493827","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459493827?lang=zh_cn&edition=full","pubTime":"2024-08-12 23:52","pubTimestamp":1723477964,"startTime":"0","endTime":"0","summary":"北京时间2024年08月12日23时52分,维罗纳制药股票出现异动,股价大幅拉升5.35%。截至发稿,该股报23.83美元/股,成交量32.4552万股,换手率0.40%,振幅5.88%。机构评级方面,在所有7家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体跌幅为1.43%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812235244aefe6e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240812235244aefe6e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"1151721551","title":"异动解读 | 维罗纳制药股价大涨5.65% 机构看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1151721551","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151721551?lang=zh_cn&edition=full","pubTime":"2024-08-09 22:12","pubTimestamp":1723212752,"startTime":"0","endTime":"0","summary":"2024年8月8日,维罗纳制药股价盘中大涨5.65%,报收20.55美元/股,成交量9.94万股,引发市场关注。分析人士认为,公司股价大涨主要源于机构对其前景的看好。维罗纳制药是一家临床阶段的生物制药公司,专注于开发治疗呼吸系统疾病的新药。最新数据显示,7家机构参与了对维罗纳制药的评级,其中100%的机构给予\"买入\"评级,看好公司长期发展前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0},{"id":"2458459902","title":"维罗纳制药盘中异动 早盘急速拉升5.42%报22.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458459902","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458459902?lang=zh_cn&edition=full","pubTime":"2024-08-09 22:07","pubTimestamp":1723212446,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日22时07分,维罗纳制药股票出现异动,股价急速上涨5.42%。截至发稿,该股报22.77美元/股,成交量12.7247万股,换手率0.16%,振幅5.23%。机构评级方面,在所有7家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。维罗纳制药股票所在的生物技术行业中,整体涨幅为1.25%。维罗纳制药公司简介:Verona Pharma PLC是一家临床阶段的生物制药公司,专注于开发和商业化治疗未满足医疗需求的呼吸系统疾病的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809220726aefe26ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809220726aefe26ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","VRNA"],"gpt_icon":0},{"id":"1107330575","title":"异动解读 | 维罗纳制药股价大涨5%,机构看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1107330575","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107330575?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:07","pubTimestamp":1723190831,"startTime":"0","endTime":"0","summary":"2024年8月8日,维罗纳制药(VRNA.US)股价盘中大涨5.02%,报收20.55美元/股,成交量9.94万股,引发市场关注。\n\n维罗纳制药是一家临床阶段的生物制药公司,专注于开发治疗呼吸系统疾病的新药。公司目前正在开发Ensifentrine候选药物,用于治疗慢性阻塞性肺疾病、囊性纤维化等疾病。\n\n分析人士认为,维罗纳制药股价大涨或与机构看好公司前景有关。最新数据显示,7家机构参与了对该股的评级,其中100%的机构给予\"买入\"评级,看好公司长期发展前景。此外,公司最新财报显示营收和净利润虽然不佳,但市场预期公司新药研发取得进展,未来业绩有望改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRNA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veronapharma.com","stockEarnings":[{"period":"1week","weight":-0.1237},{"period":"1month","weight":0.009},{"period":"3month","weight":0.2719},{"period":"6month","weight":1.773},{"period":"1year","weight":1.4014},{"period":"ytd","weight":0.7575}],"compareEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":0.0061},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.2374}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"维罗纳制药公司根据英格兰及威尔士的法律以Isis Resources plc为名于2005年2月24日注册成立。2006年9月,该公司收购了在加拿大注册成立的私人公司Rhinopharma Limited,并更名为维罗纳制药公司。该公司是一家临床阶段的生物制药公司,专注于开发和商业化创新治疗方法,用于治疗具有显著未满足的医疗需求的呼吸系统疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081831},{"month":2,"riseRate":0.428571,"avgChangeRate":0.024379},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.014175},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.063776},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026344},{"month":6,"riseRate":0.25,"avgChangeRate":-0.037719},{"month":7,"riseRate":0.625,"avgChangeRate":0.1404},{"month":8,"riseRate":0.5,"avgChangeRate":0.11834},{"month":9,"riseRate":0.375,"avgChangeRate":0.007343},{"month":10,"riseRate":0.25,"avgChangeRate":-0.009258},{"month":11,"riseRate":0.375,"avgChangeRate":-0.010803},{"month":12,"riseRate":0.714286,"avgChangeRate":0.313093}],"exchange":"NASDAQ","name":"维罗纳制药","nameEN":"Verona Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维罗纳制药(VRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维罗纳制药(VRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维罗纳制药,VRNA,维罗纳制药股票,维罗纳制药股票老虎,维罗纳制药股票老虎国际,维罗纳制药行情,维罗纳制药股票行情,维罗纳制药股价,维罗纳制药股市,维罗纳制药股票价格,维罗纳制药股票交易,维罗纳制药股票购买,维罗纳制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维罗纳制药(VRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维罗纳制药(VRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}